MCID: ADL096
MIFTS: 48

Adult Hepatocellular Carcinoma

Categories: Liver diseases, Rare diseases, Cancer diseases, Genetic diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Adult Hepatocellular Carcinoma

MalaCards integrated aliases for Adult Hepatocellular Carcinoma:

Name: Adult Hepatocellular Carcinoma 59
Adult Primary Hepatocellular Carcinoma 73
Adult Hcc 59

Characteristics:

Orphanet epidemiological data:

59
adult hepatocellular carcinoma
Inheritance: Not applicable;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

Orphanet 59 ORPHA210159
ICD10 via Orphanet 34 C22.0

Summaries for Adult Hepatocellular Carcinoma

MalaCards based summary : Adult Hepatocellular Carcinoma, also known as adult primary hepatocellular carcinoma, is related to hepatocellular carcinoma and rare adenocarcinoma of the breast, and has symptoms including abdominal pain, fever and icterus. An important gene associated with Adult Hepatocellular Carcinoma is AXIN1 (Axin 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Sorafenib and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and kidney, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Adult Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Adult Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 26.9 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
2 rare adenocarcinoma of the breast 10.5 PIK3CA TP53
3 malignant spiradenoma 10.4 PIK3CA TP53
4 multilocular clear cell renal cell carcinoma 10.4 TSC1 TSC2
5 subependymal glioma 10.4 TSC1 TSC2
6 kidney angiomyolipoma 10.4 TSC1 TSC2
7 benign ependymoma 10.4 TSC1 TSC2
8 breast squamous cell carcinoma 10.4 PIK3CA TP53
9 anal squamous cell carcinoma 10.4 PIK3CA TP53
10 tuberous sclerosis 1 10.4 TSC1 TSC2
11 lissencephaly with cerebellar hypoplasia 10.4 TSC1 TSC2
12 kidney benign neoplasm 10.3 TSC1 TSC2
13 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.3 TSC1 TSC2
14 esophagus adenocarcinoma 10.3 PIK3CA TP53
15 prostate squamous cell carcinoma 10.3 PIK3CA TP53
16 subependymal giant cell astrocytoma 10.3 TSC1 TSC2
17 corneal dystrophy, fleck 10.3 TSC1 TSC2
18 brain stem glioma 10.2 PIK3CA TP53
19 ovarian clear cell carcinoma 10.1 PIK3CA TP53
20 prostate transitional cell carcinoma 10.1 CTNNB1 PIK3CA
21 cowden disease 10.1 PIK3CA TSC1 TSC2
22 skin squamous cell carcinoma 10.0 PIK3CA TP53
23 oral cavity cancer 10.0 CASP8 PIK3CA TP53
24 tuberous sclerosis 10.0 PIK3CA TSC1 TSC2
25 hemimegalencephaly 10.0 CTNNB1 PIK3CA
26 angiomyolipoma 9.9 TSC1 TSC2
27 focal cortical dysplasia, type ii 9.9 TP53 TSC1 TSC2
28 female reproductive endometrioid cancer 9.8 CTNNB1 TP53
29 lymphoma, non-hodgkin, familial 9.8 CASP8 PIK3CA TP53
30 epstein-barr virus-associated gastric carcinoma 9.8 CTNNB1 PIK3CA
31 bladder squamous cell carcinoma 9.8 PIK3CA TP53
32 central nervous system organ benign neoplasm 9.8 CTNNB1 TP53
33 polycystic kidney disease 1 with or without polycystic liver disease 9.7 EGF TSC1 TSC2
34 autosomal dominant polycystic kidney disease 9.7 EGF TSC1 TSC2
35 signet ring cell adenocarcinoma 9.7 CTNNB1 TP53
36 fibrolamellar carcinoma 9.7
37 acinar cell carcinoma 9.6 CTNNB1 TP53
38 gastrointestinal system benign neoplasm 9.6 CTNNB1 TP53
39 glioblastoma multiforme 9.6 EGF PIK3CA TP53
40 esophageal basaloid squamous cell carcinoma 9.5 AXIN1 CTNNB1 TP53
41 embryonal sarcoma 9.5 AXIN1 CTNNB1 TP53
42 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 9.5 CTNNB1 PIK3CA TP53
43 familial adenomatous polyposis 9.5 AXIN1 CTNNB1 TP53
44 suppression of tumorigenicity 12 9.5 CTNNB1 PIK3CA TP53
45 female reproductive organ cancer 9.5 CTNNB1 PIK3CA TP53
46 respiratory system cancer 9.5 CTNNB1 PIK3CA TP53
47 uterine carcinosarcoma 9.5 CTNNB1 PIK3CA TP53
48 gastrointestinal system cancer 9.5 CTNNB1 PIK3CA TP53
49 adrenocortical carcinoma, hereditary 9.5 CTNNB1 PIK3CA TP53
50 pancreas adenocarcinoma 9.5 CTNNB1 PIK3CA TP53

Graphical network of the top 20 diseases related to Adult Hepatocellular Carcinoma:



Diseases related to Adult Hepatocellular Carcinoma

Symptoms & Phenotypes for Adult Hepatocellular Carcinoma

UMLS symptoms related to Adult Hepatocellular Carcinoma:


abdominal pain, fever, icterus, malaise

MGI Mouse Phenotypes related to Adult Hepatocellular Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
2 growth/size/body region MP:0005378 10.06 EGF PIK3CA TP53 TSC1 TSC2 AXIN1
3 cellular MP:0005384 10.05 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
4 embryo MP:0005380 10.04 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
5 endocrine/exocrine gland MP:0005379 10.02 CASP8 CTNNB1 EGF PIK3CA TP53 TSC1
6 integument MP:0010771 9.98 EGF PIK3CA TP53 TSC1 TSC2 CASP8
7 liver/biliary system MP:0005370 9.8 CASP8 CTNNB1 TP53 TSC1 TSC2
8 neoplasm MP:0002006 9.8 CASP8 CTNNB1 PIK3CA TP53 TSC1 TSC2
9 nervous system MP:0003631 9.8 AXIN1 CASP8 CTNNB1 PIK3CA TP53 TSC1
10 muscle MP:0005369 9.77 CASP8 CTNNB1 PIK3CA TP53 TSC1
11 renal/urinary system MP:0005367 9.63 AXIN1 CASP8 CTNNB1 TP53 TSC1 TSC2
12 reproductive system MP:0005389 9.5 AXIN1 CTNNB1 EGF PIK3CA TP53 TSC1
13 respiratory system MP:0005388 9.02 AXIN1 CASP8 CTNNB1 TP53 TSC1

Drugs & Therapeutics for Adult Hepatocellular Carcinoma

Drugs for Adult Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
2
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
3
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-92-0 936
4
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-67-6 938
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
6 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Nicotinic Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Analgesics Phase 4,Phase 2,Phase 1
14 Central Nervous System Depressants Phase 4,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
16 Calcium, Dietary Phase 4,Phase 2,Phase 1
17 calcium channel blockers Phase 4
18 Tranquilizing Agents Phase 4
19 Anti-Anxiety Agents Phase 4
20 Anticonvulsants Phase 4
21 Psychotropic Drugs Phase 4
22 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Vitamin B3 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
27
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
28
Iodine Approved, Investigational Phase 3 7553-56-2 807
29
Ethiodized oil Approved, Investigational Phase 3 8008-53-5
30
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
31
Sunitinib Approved, Investigational Phase 2, Phase 3 341031-54-7, 557795-19-4 5329102
32
Tamoxifen Approved Phase 3 10540-29-1 2733526
33
Pravastatin Approved Phase 3,Phase 2 81093-37-0 54687
34
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
35
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
37
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
38 Nolatrexed Investigational Phase 3 147149-76-6
39
Tremelimumab Investigational Phase 3 745013-59-6
40 cadexomer iodine Phase 3
41 Coagulants Phase 2, Phase 3
42 Hemostatics Phase 2, Phase 3
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
44 Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
46 Hormones Phase 3,Phase 2,Phase 1
47 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver Recruiting NCT03151213 Phase 4 Pregabalin 150mg
2 HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) Terminated NCT01849588 Phase 4 Sorafenib
3 Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Unknown status NCT01324076 Phase 3 doxorubicin-eluting beads;sorafenib tosylate
4 Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) Unknown status NCT00079027 Phase 3 doxorubicin hydrochloride
5 Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer Unknown status NCT00027768 Phase 3
6 Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery Unknown status NCT01655641 Phase 2, Phase 3 Tranexamic acid
7 A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC Completed NCT01829035 Phase 3
8 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
9 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed NCT01164202 Phase 2, Phase 3 sunitinib malate;Placebo
10 Tamoxifen in Treating Patients With Primary Liver Cancer Completed NCT00003424 Phase 3 tamoxifen citrate
11 Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed NCT00041275 Phase 3 megestrol acetate
12 Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis Completed NCT01075555 Phase 3 pravastatin sodium;sorafenib tosylate
13 Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer Completed NCT00870558 Phase 3 ethiodized oil
14 Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery Completed NCT00109954 Phase 3 cisplatin
15 Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer Completed NCT00012324 Phase 3 doxorubicin hydrochloride;nolatrexed dihydrochloride
16 TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer Recruiting NCT02794337 Phase 2, Phase 3 Sorafenib
17 Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02645981 Phase 2, Phase 3 Donafenib;Sorafenib
18 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Recruiting NCT01730937 Phase 3 sorafenib tosylate
19 Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Recruiting NCT03298451 Phase 3 Durvalumab;Tremelimumab (Regimen 1);Tremelimumab (Regimen 2);Sorafenib;Durvalumab (Regimen 1);Durvalumab (Regimen 2)
20 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Active, not recruiting NCT01387932 Phase 3
21 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Active, not recruiting NCT01015833 Phase 3 Doxorubicin Hydrochloride;Sorafenib Tosylate
22 Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study Not yet recruiting NCT02702323 Phase 2, Phase 3 Apatinib
23 Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma Terminated NCT01405573 Phase 3 sorafenib
24 Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02418988 Phase 2 TACE plus rAd-p53 artery injection;TACE
25 Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer Unknown status NCT00006198 Phase 2 thalidomide
26 Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm Unknown status NCT02528526 Phase 1, Phase 2 OXY111A
27 Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery Unknown status NCT01182272 Phase 2 sorafenib tosylate
28 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis Unknown status NCT00132041 Phase 2
29 Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors Unknown status NCT00374660 Phase 1, Phase 2 Irofulven + oxaliplatin
30 Sorafenib Tosylate With or Without Gemcitabine Hydrochloride and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer Unknown status NCT00941967 Phase 2 gemcitabine hydrochloride;oxaliplatin;sorafenib tosylate
31 Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
32 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
33 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
34 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
35 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
36 Sorafenib and TRC105 in Hepatocellular Cancer Completed NCT01306058 Phase 1, Phase 2 TRC 105;Sorafenib
37 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial Completed NCT00717756 Phase 2 lenalidomide
38 Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 Completed NCT00775073 Phase 2 Everolimus, Bevacizumab
39 Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy Completed NCT00627042 Phase 2
40 A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer Completed NCT00872014 Phase 2 AMG 386;AMG 386;Sorafenib
41 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed NCT02024087 Phase 1, Phase 2 Dalantercept plus sorafenib
42 Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Completed NCT01777594 Phase 2 G-202
43 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Completed NCT01488487 Phase 2 Everolimus;Pasireotide
44 Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Completed NCT00006016 Phase 2 thalidomide;doxorubicin hydrochloride
45 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer Completed NCT00055692 Phase 2
46 Oxaliplatin in Treating Patients With Liver Cancer Completed NCT00052364 Phase 2 oxaliplatin
47 Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer Completed NCT00365391 Phase 2 erlotinib hydrochloride
48 Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed Completed NCT00006006 Phase 2 thalidomide
49 Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients Completed NCT02089919 Phase 1, Phase 2
50 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer Completed NCT00355238 Phase 2 brivanib (active)

Search NIH Clinical Center for Adult Hepatocellular Carcinoma

Genetic Tests for Adult Hepatocellular Carcinoma

Anatomical Context for Adult Hepatocellular Carcinoma

MalaCards organs/tissues related to Adult Hepatocellular Carcinoma:

41
Liver, T Cells, Kidney, Bone, Bone Marrow, Endothelial, Myeloid

Publications for Adult Hepatocellular Carcinoma

Articles related to Adult Hepatocellular Carcinoma:

# Title Authors Year
1
Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. ( 29602016 )
2018
2
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. ( 26990031 )
2016
3
Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. ( 10847487 )
2000

Variations for Adult Hepatocellular Carcinoma

Expression for Adult Hepatocellular Carcinoma

Search GEO for disease gene expression data for Adult Hepatocellular Carcinoma.

Pathways for Adult Hepatocellular Carcinoma

Pathways related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
2
Show member pathways
13.65 AXIN1 CASP8 CTNNB1 EGF TP53 TSC1
3
Show member pathways
13.11 AXIN1 CASP8 CTNNB1 EGF TSC1 TSC2
4
Show member pathways
12.77 EGF PIK3CA TSC1 TSC2
5
Show member pathways
12.68 AXIN1 CASP8 PIK3CA TP53
6
Show member pathways
12.63 EGF PIK3CA TP53 TSC1 TSC2
7
Show member pathways
12.62 AXIN1 CTNNB1 EGF PIK3CA TP53
8
Show member pathways
12.59 EGF PIK3CA TP53 TSC2
9
Show member pathways
12.59 AXIN1 CTNNB1 EGF PIK3CA TP53 TSC2
10
Show member pathways
12.53 CASP8 CTNNB1 PIK3CA TSC2
11 12.52 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
12
Show member pathways
12.45 CASP8 CTNNB1 PIK3CA TP53
13
Show member pathways
12.38 AXIN1 CASP8 CTNNB1 EGF PIK3CA TP53
14
Show member pathways
12.33 CASP8 CTNNB1 PIK3CA TP53
15
Show member pathways
12.32 PIK3CA TP53 TSC1 TSC2
16
Show member pathways
12.32 CASP8 CTNNB1 EGF PIK3CA TP53
17 12.31 CTNNB1 PIK3CA TP53
18
Show member pathways
12.3 PIK3CA TSC1 TSC2
19
Show member pathways
12.29 EGF PIK3CA TSC1 TSC2
20
Show member pathways
12.27 CASP8 TP53 TSC2
21
Show member pathways
12.26 AXIN1 PIK3CA TP53 TSC1 TSC2
22 12.19 CTNNB1 PIK3CA TP53
23 12.18 CASP8 PIK3CA TP53
24 12.08 CTNNB1 EGF TP53
25
Show member pathways
12.06 CTNNB1 EGF PIK3CA
26 12.05 PIK3CA TP53 TSC1 TSC2
27 12.05 PIK3CA TP53 TSC1 TSC2
28
Show member pathways
12.03 AXIN1 CTNNB1 TP53
29
Show member pathways
12.02 CASP8 PIK3CA TSC2
30 12 AXIN1 CASP8 CTNNB1
31
Show member pathways
12 PIK3CA TP53 TSC1 TSC2
32 11.98 CTNNB1 PIK3CA TP53
33 11.98 AXIN1 CTNNB1 PIK3CA
34
Show member pathways
11.98 CTNNB1 EGF PIK3CA TSC2
35 11.95 AXIN1 CTNNB1 TP53
36 11.95 EGF PIK3CA TP53
37 11.94 PIK3CA TSC1 TSC2
38
Show member pathways
11.92 CASP8 PIK3CA TP53
39
Show member pathways
11.9 PIK3CA TP53 TSC1 TSC2
40 11.84 CTNNB1 PIK3CA TP53 TSC2
41 11.82 AXIN1 CTNNB1 PIK3CA TP53
42 11.77 PIK3CA TSC1 TSC2
43 11.74 CASP8 CTNNB1 TP53 TSC1 TSC2
44 11.73 TP53 TSC1 TSC2
45 11.66 CASP8 PIK3CA TP53
46 11.38 TP53 TSC1 TSC2
47
Show member pathways
11.35 EGF PIK3CA
48 11.33 CTNNB1 EGF
49 11.28 AXIN1 CTNNB1 TSC1 TSC2
50 11.25 TSC1 TSC2

GO Terms for Adult Hepatocellular Carcinoma

Cellular components related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.56 AXIN1 CTNNB1 TSC1 TSC2
2 lamellipodium GO:0030027 9.33 CTNNB1 PIK3CA TSC1
3 beta-catenin destruction complex GO:0030877 8.96 AXIN1 CTNNB1
4 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.81 AXIN1 CTNNB1 EGF TP53
2 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 9.76 AXIN1 CTNNB1 TP53
3 negative regulation of cell proliferation GO:0008285 9.67 CTNNB1 TP53 TSC1 TSC2
4 cell cycle arrest GO:0007050 9.63 TP53 TSC1 TSC2
5 ERBB2 signaling pathway GO:0038128 9.59 EGF PIK3CA
6 response to antibiotic GO:0046677 9.58 CASP8 TP53
7 negative regulation of TOR signaling GO:0032007 9.57 TSC1 TSC2
8 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.56 CASP8 TP53
9 negative regulation of insulin receptor signaling pathway GO:0046627 9.55 TSC1 TSC2
10 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.54 AXIN1 EGF
11 positive regulation of macroautophagy GO:0016239 9.52 TSC1 TSC2
12 vasculature development GO:0001944 9.49 CTNNB1 PIK3CA
13 beta-catenin destruction complex disassembly GO:1904886 9.48 AXIN1 CTNNB1
14 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 AXIN1 EGF
15 negative regulation of macroautophagy GO:0016242 9.4 PIK3CA TSC1
16 negative regulation of oxidative stress-induced neuron death GO:1903204 9.32 CTNNB1 TSC1
17 anoikis GO:0043276 9.26 PIK3CA TSC2
18 regulation of protein localization to cell surface GO:2000008 9.16 CTNNB1 EGF
19 regulation of calcium ion import GO:0090279 8.96 CTNNB1 EGF
20 canonical Wnt signaling pathway GO:0060070 8.8 AXIN1 CTNNB1 EGF

Molecular functions related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 9.26 TSC1 TSC2
2 disordered domain specific binding GO:0097718 9.16 CTNNB1 TP53
3 I-SMAD binding GO:0070411 8.96 AXIN1 CTNNB1
4 binding GO:0005488 8.92 CTNNB1 PIK3CA TSC1 TSC2

Sources for Adult Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....